Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01171924 | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors | completed | Phase 1 | 47 | Curis, Inc.INDUSTRY | 1 | Mar 1, 2016 | clinicaltrials |
| NCT00129012 | Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 30 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 |
| clinicaltrials |
| NCT01769066 | Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC | completed | Phase 2 / Phase 3 | 117 | Fudan UniversityOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01810367 | ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC | completed | Phase 2 | 84 | Fudan UniversityOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00940069 | TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer(TPEIAL) | completed | Phase 2 | 60 | Hunan Province Tumor HospitalOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00961415 | AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 376 | Hoffmann-La RocheINDUSTRY | 12 | Feb 22, 2016 | clinicaltrials |
| NCT02256852 | Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer | completed | Phase 2 | 6 | Qu Biologics Inc.INDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01985113 | Correlation Research of Thioredoxin Reductase in Lung Cancer(TRCRLC) | completed | — | 165 | Hunan Province Tumor HospitalOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01991418 | Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) | completed | — | 165 | Hunan Province Tumor HospitalOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00035516 | A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy | completed | Phase 2 | — | R-PharmINDUSTRY | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00770588 | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)(INFORM) | completed | Phase 4 | 296 | AstraZenecaINDUSTRY | 1 | Feb 8, 2016 | clinicaltrials |
| NCT00423449 | Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) | completed | Phase 1 | 61 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2016 | clinicaltrials |
| NCT00579683 | Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer | completed | — | 228 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT01372384 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01402089 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | completed | Phase 4 | 54 | Markus JoergerOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01609543 | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | completed | Phase 4 | 62 | Hoffmann-La RocheINDUSTRY | 3 | Feb 1, 2016 | clinicaltrials |
| NCT01836679 | Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Feb 1, 2016 | clinicaltrials |
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | completed | Phase 2 | 202 | SCRI Development Innovations, LLCOTHER | 1 | Jan 29, 2016 | clinicaltrials |
| NCT01022671 | Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy | completed | Phase 2 | 52 | Chong Kun Dang PharmaceuticalINDUSTRY | 0 | Jan 28, 2016 | clinicaltrials |
| NCT01326767 | Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring(CEPAC-TDM) | completed | Phase 3 | 366 | Central European Society for Anticancer Drug ResearchOTHER | 2 | Jan 27, 2016 | clinicaltrials |
| NCT01137968 | Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 116 | Geron CorporationINDUSTRY | 3 | Jan 26, 2016 | clinicaltrials |
| NCT01823094 | CTP Imaging of Lung Cancer(CTPLC) | completed | — | 14 | University of California, DavisOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00130780 | Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC | completed | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02595450 | A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer | completed | — | 299 | Hoffmann-La RocheINDUSTRY | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00588445 | Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene | completed | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01684111 | An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)(VENUS-1) | completed | Phase 1 | 7 | Aktion Bronchialkarzinom e.V.OTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT00349219 | TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer(TORCH) | completed | Phase 3 | 760 | National Cancer Institute, NaplesOTHER | 2 | Jan 15, 2016 | clinicaltrials |
| NCT00534027 | A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 172 | AmgenINDUSTRY | 0 | Jan 14, 2016 | clinicaltrials |
| NCT00779389 | Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family | completed | Phase 1 | 58 | University of PittsburghOTHER | 1 | Jan 13, 2016 | clinicaltrials |
| NCT02000531 | Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population | completed | Phase 4 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Jan 13, 2016 | clinicaltrials |
| NCT01874678 | A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer | completed | N/A | 45 | TTY BiopharmINDUSTRY | 1 | Jan 12, 2016 | clinicaltrials |
| NCT02038413 | State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients(Lung stage I) | completed | — | 25 | Maastricht Radiation OncologyOTHER | 1 | Jan 12, 2016 | clinicaltrials |
| NCT01185847 | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 7 | Jan 1, 2016 | clinicaltrials |
| NCT02645318 | Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer | completed | — | 95 | Peking University People's HospitalOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT01664533 | An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy(TIME) | completed | — | 57 | Hoffmann-La RocheINDUSTRY | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00112294 | Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 755 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT01109524 | Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 3 | Dec 24, 2015 | clinicaltrials |
| NCT00762034 | A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 21, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT00883779 | A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 3 | 451 | Hoffmann-La RocheINDUSTRY | 7 | Dec 14, 2015 | clinicaltrials |
| NCT00861627 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | completed | Phase 2 | 37 | Oncolytics BiotechINDUSTRY | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT01482182 | Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy | completed | — | 35 | Samsung Medical CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00157209 | Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) | completed | Phase 2 | 171 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01204697 | A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) | completed | Phase 2 | 74 | Hoffmann-La RocheINDUSTRY | 1 | Nov 16, 2015 | clinicaltrials |
| NCT01535729 | An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | completed | — | 465 | Hoffmann-La RocheINDUSTRY | 1 | Oct 29, 2015 | clinicaltrials |
| NCT00112346 | Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 120 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT00162318 | A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00207116 | An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma | completed | Phase 1 | 120 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Mar 1, 2016source: clinicaltrials